Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan · Delayed Price · Currency is TWD 102.00
-0.50 (-0.49%)
Sep 5, 2025, 1:30 PM CST
Gongwin Biopharm Holdings Market Cap
Gongwin Biopharm Holdings has a market cap or net worth of 12.51 billion as of September 5, 2025. Its market cap has increased by 8.72% in one year.
Market Cap
12.51B
Enterprise Value
10.84B
Revenue
34.47M
Ranking
n/a
PE Ratio
n/a
Stock Price
102.00
Market Cap Chart
Since February 8, 2017, Gongwin Biopharm Holdings's market cap has increased from 8.87B to 12.51B, an increase of 41.06%. That is a compound annual growth rate of 4.09%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 5, 2025 | 12.51B | -12.96% |
| Dec 31, 2024 | 14.37B | -31.28% |
| Dec 29, 2023 | 20.91B | -42.13% |
| Dec 30, 2022 | 36.13B | 16.16% |
| Dec 30, 2021 | 31.10B | 17.15% |
| Dec 31, 2020 | 26.55B | 222.07% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Feb 8, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Caliway Biopharmaceuticals | 395.51B |
| PharmaEssentia | 169.97B |
| Bora Pharmaceuticals Co., LTD. | 90.84B |
| Lotus Pharmaceutical | 50.62B |
| Lumosa Therapeutics | 40.77B |
| Oneness Biotech | 36.44B |
| Polaris Group | 29.47B |
| Center Laboratories | 28.63B |